Preventing cervical cancer by Botha, M. H. (Hennie)
Cervical cancer remains the most common cancer diagnosed in 
women in southern Africa, with an estimated lifetime risk of 1 in 
26.1  Unfortunately most of these cancers are also diagnosed at a 
late stage, with subsequent poor prognosis for long-term survival. 
This very high incidence is particularly sad in an era where 
advances in medical science have made cervical cancer a mostly 
preventable disease.  In most developed economies cervical cancer 
has become a less common occurrence due to intensive screening 
and preventive strategies.
We are entering an exciting new era in the fight against cervical 
cancer with new vaccine technology becoming available.  Vaccines 
against oncogenic (cancer causing) strains of human papillomavirus 
(HPV) will hopefully reduce cervical cancer rates globally even 
further and provide hope for South Africa.  Professor Harald Zur 
Hausen was awarded the Nobel Prize for physiology and medicine 
in 2008 for his very important work on papillomaviruses and 
cervical carcinogenesis.2 This highlights the progress that has been 
made over the last few years in terms of the understanding of 
cervical cancer aetiology and new strategies for prevention.
Aetiology of cervical cancer
Persistent infection with an oncogenic strain of HPV is a necessary 
risk factor for the development of cervical cancer.3 Oncogenic types 
of HPV have the ability to integrate certain parts of the viral DNA 
into the human genome. The oncoproteins E6 and E7 inactivate 
very important processes associated with tumour-suppressor 
genes like P53 and PRb gene functions. Low-risk HPV infection 
is associated with warts on the epithelial surfaces of the genital 
area but also warts on hands and feet.  It is important to recognise 
that low-risk HPV types causing plantar warts and warts on the 
skin are not associated with cancer but belong to the same family 
of papillomaviruses.  HPV is highly infectious and ‘most sexually 
active people will get HPV at some time in their lives’, making it 
a very common sexually transmitted infection.4  This ubiquitous 
infection does not cause disease in all the infected individuals 
and certain processes make individuals more susceptible to the 
formation of pre-malignant and malignant disease.  Because 
HPV is mostly an epithelial disease the virus is poorly presented 
to the adaptive immune system, which is important for induction 
of long-term immunity.  Most natural infections of HPV do not 
cause significant immunoglobulin responses and therefore the 
immune response after natural infections is not very pronounced.5 
After initial exposure to HPV there is an incubation period of 
1 - 8 months, after which the first HPV-related lesions might appear. 
There is active growth of the virus for a period of 3 - 6 months 
but usually there are host-immune responses that will, in most 
cases, clear the infection by about 9 months.  A large percentage 
of the population will have sustained clinical remission but a small 
proportion will develop resistant or recurrent disease and become 
HPV-DNA positive on repeated testing.  These are the individuals 
who will be at highest risk for the development of pre-malignant 
conditions and later invasive cancer. We now know that changes in 
cells due to HPV infection of the cervix are the first step in a series 
of slow changes that can lead to cancer years later. 
Prevention of disease
Disease prevention strategies can be categorised into primary 
prevention, secondary prevention and tertiary prevention. 
Primary prevention aims to reduce the risk of an individual getting 
a particular disease by reducing the disease-causing agents in the 
environment.  In the case of cervical cancer the most important 
aetiological factor for the development of pre-malignant and 
malignant disease is persistent infection with oncogenic types 
of HPV infection.  By reducing the risk for HPV infection the 
incidence of cervical cancer should decrease drastically.  These 
may include measures like education about safe sexual practices 
including mutual monogamy and barrier contraceptive use 
(although this is not fully protective against HPV infection). 
Recently vaccination against HPV infection has become available 
in South Africa. The very strong association between HIV infection 
with papillomavirus-associated disease also gives the opportunity 
for primary prevention by reducing HIV seropositivity.  Other risk 
factors include smoking, long-term use of oral contraceptives and 
high parity.
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South African women with cervical cancer often present late and have 
a poor prognosis as a result.
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Secondary prevention of cervical cancer 
involves screening for early diagnosis 
and treatment of pre-cancerous lesions. 
Secondary screening methods are described 
below.  
Tertiary prevention of disease aims to down-
stage the disease. When detecting the 
disease at an earlier stage, simpler forms of 
treatment may still be given successfully.  A 
good example is visual inspection with acetic 
acid of the cervix to identify early invasive 
cancers or pre-malignant conditions. This 
strategy was tested in a large study from 
India and it was shown that it can reduce 





Over the last 20 years scientists have 
developed a progressively better 
understanding of the pathogenesis of HPV 
infection and cervical cancer.  This has led 
to the development of vaccines against HPV 
infection.2 Virus-like particles (VLPs) that 
do not contain any virus DNA have been 
produced in the laboratory. These VLPs, 
when injected into the human circulation, 
elicit a strong immune response. These 
vaccines have produced fantastic results 
in terms of protection against disease and 
persistent infection and are now widely used 
in many different parts of the world.7,8  The 
VLP vaccines are very safe and have been 
extensively studied in large populations. 
Currently there are two registered vaccines 
for HPV vaccination, namely Cervarix 
containing HPV types 16 and 18 and 
Gardasil, which protects against HPV 16 and 
18 and also two low-risk types, numbers 6 
and 11. HPV 6 and 11 are the most common 
viruses causing genital warts.  Both vaccines 
have been studied in large populations 
and have been found to be safe, effective 
and well tolerated.  The virus-like particles 
are combined with an immune stimulant 
called an adjuvant which leads to improved 
immunoglobulin production against the 
vaccine types of VLPs.  It has been shown 
recently that the vaccines protect against 
more types of HPV infection than just those 
that are present in the vaccines.9  Cervarix 
has been shown to have excellent cross-
protection against types 31 and 45 and 
Gardasil has shown partial cross-protection 
against types 31, 33, 45, 52 and 58. At 
present the exact period of protection is not 
known, but longitudinal studies over more 
than 7 years have shown that these vaccines 
will most likely be protective for a very long 
period of time and a booster should not 
be necessary.  Both vaccines have a 3-dose 
schedule, with the second dose after 1 or 
2 months and a third dose after 6 months. 
In order for the vaccine to be effective 
in preventing HPV infection, it must be 
given before exposure to HPV.  This is of 
course before exposure to sexual contact. 
There may be some differences between 
populations, but in general most authorities 
feel that girls around the age of 11 - 12 years, 
just before leaving primary school, may be 
the most suitable for mass vaccination.   
High vaccine coverage is needed if significant 
improvement of cervical cancer rates is to be 
achieved.  In many First-World countries 
the introduction of the vaccines has been 
rapid and very well organised.  Examples 
of well-organised vaccination programmes 
for girls are the National Health Service 
in the UK and the Australian government 
programme.  Both these programmes aim 
to vaccinate all girls around the age of 12 
but for the first few years also include a 
catch-up group of slightly older women. 
At present most national or regional 
vaccination programmes do not include 
boys, but it makes sense to include them 
when the vaccines become less expensive.10 
The uptake of these vaccines has been good, 
with an acceptance rate of over 80% in both 
Australia and the UK.  In South Africa 
Gardasil and Cervarix are both available 
in the private sector and are currently 
being considered for a national vaccination 
programme.  A vaccination programme in 
South Africa will almost certainly make a 
significant difference in the cervical cancer 
incidence within a few years.  South Africa 
has a high rate of infant vaccination and the 
principles of vaccination are well known to 
health care professionals. The benefit over 
the medium to long term will be enormous 
in terms of cost of treatment and diagnosis 
of pre-malignant and malignant cervical 
disease.  The commercially available vaccines 
are listed in Table I.
Secon dary prevention of 
cervical cancer
Cervical cytology
George Papanicolaou initially described 
the examination of posterior vaginal fornix 
cells to detect precursors for cervical cancer 
in 1928.  A subsequent publication in 1941 
was one of the most important articles in 
the history of cancer screening.  Since then 
few modifications were introduced. Ayre, 
in 1947, introduced the wooden spatula. 
Cervical cytology (Pap test) remains a 
highly effective and trusted screening 
tool for cervical cancer.  Regular cytology 
smears, combined with treatment of pre-
malignant lesions, can reduce the incidence 
of cervical cancer drastically if it is used on 
a high proportion of the entire population. 
Opportunistic screening may be effective 
in certain populations where patient 
education and motivation are high, but for 
a programme to work well a population-
based screening policy is more effective.  In 
certain parts of South Africa (particularly in 
the private sector) opportunistic screening 
with regular Pap smears has resulted in 
a significant drop in the rate of cervical 
cancer. The national policy for cervical 
cancer screening in the public sector was 
introduced in 2000 by the Department of 
Health.  With this programme every woman 
in South Africa should have three cytology 
smears 10 years apart, starting at the age 
of 30.  This is a good model and compares 
well with the World Health Organization 
suggestion of a single screen per woman per 
lifetime in low-income countries. However, 
Most natural 
infections of 







infections is not 
very pronounced.
Table I. Commercially available HPV vaccines 
Vaccine Gardasil Cervarix
HPV types 6, 11, 16, 18 16, 18
Dosing schedule 0, 2, 6 months 0, 1, 6 months
Adjuvant AAHS (amorphous  ASO4 (aluminum 
 aluminum hydroxyphosphate  hydroxide + MPL) 
 sulfate)
VLP preparation  
system Yeast Insect cell 
Efficacy against disease  
caused by HPV types in  
the vaccine 100%11  98.1%8   
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in the state sector the national cytology 
screening programme has not been 
implemented widely. 
Liquid-based cytology is a similar 
technique, where the collected cells are 
transported in liquid to the laboratory. 
This method of preparation of cervical 
cytology may decrease the false-negative 
rate of standard Pap smears. Liquid-based 
cytology uses the same principle as the 
Pap smear but the technique may have a 
slightly better sensitivity and specificity for 
the diagnosis of high-grade intra-epithelial 
lesions. 
The term now used in cytological screening 
of Pap smears is ‘squamous intraepithelial 
lesion’ (SIL). 
Low-grade squamous intraepithelial 
lesion (LSIL) refers to early changes in 
the size, shape and nuclei of cells. Most 
low-grade lesions clear on their own. 
However, with time, others may become 
more abnormal, forming a high-grade 
lesion. It is usually not necessary to treat 
or investigate further when LSIL is present 
on a cytology smear. This is however an 
indication that the test should be repeated 
a few months later and if the LSIL is still 
present on the repeat it will need further 
investigation.
High-grade squamous intraepithelial 
lesion (HSIL) means there are a larger 
number of more abnormal pre-cancerous 
cells. In the past, these lesions were referred 
to as moderate or severe dysplasia, or 
carcinoma in situ. When HSIL is found on 
a Pap smear further tests like a colposcopy 
or Lletz are necessary.
If intraepithelial neoplastic cells break 
through the basement membrane, the 
disease is regarded as invasive cervical 
cancer.
Human papillomavirus DNA 
testing
Recently technology for the testing of 
specific human papillomavirus types 
has improved dramatically.  The newest 
generation of HPV tests is very accurate 
and will detect very low numbers of virus 
particles in any given sample.  Broadly 
there are two types of HPV tests, the first 
being a test for a ‘basket’ of high-grade 
viruses (usually 16, 18, 31, 33, 35, 39, 45, 
51, 52, 56, 58, 59 and 68). One example is 
the hybrid capture II test. The other type of 
HPV test is called genotyping and tests for 
many single types of HPV.  The newer tests 
use polymerase chain reaction (PCR) and 
are completely automated. Genotyping 
HPV tests are available at most private 
pathology laboratories in South Africa 
and are relatively expensive.  The first type, 
the so-called ‘basket test’, usually gives 
simple yes/no answers for the positivity of 
high-grade HPV types.  HPV genotyping 
however is reported on a strip where the 
different HPV types will create a colour 
development reaction if present in the 
sample.  It is therefore possible to see the 
exact types of HPV present in the sample, 
even at very, very low concentrations. 
HPV testing has a very high sensitivity for 
the detection of HSIL lesions. Even if the 
specificity is significantly lower than that 
of cytology, it has an excellent negative 
predictive value and the test can be done 
on dry or wet samples.  It is easy to include 
HPV testing in a liquid-based cytology 
setting.  In future it may even be possible 
that a patient may self-collect samples of 
HPV in the form of a self-administered 
vaginal swab or even a tampon.
If HPV testing is to be used as a screening 
tool, it is important to only test women 
over the age of 35.  If younger women 
are tested the incidence of HPV infection 
will be very high and the detection rate 
for true histological abnormality will be 
disappointingly low.  If, however, older 
women test positive for HPV, the chances 
are that they have persistent infection with 
concomitant cytological abnormalities. 
This may become the screening test of 
choice in a vaccinated population.12
At present cervical cytology remains the 
cornerstone of cervical cancer screening. 
However, 4 - 10% of cytology smears 
are reported as atypical squamous cells 
of undetermined significance (ASCUS) 
that may make management difficult. 
HPV testing in these patients may help to 
triage patients for further management. 
There is strong evidence to support this 
strategy.13
Visual inspection with acetic acid
Visual inspection with acetic acid of the 
cervix is a method used in low-resource 
settings to identify early invasive cancers 
or pre-malignant conditions. The cervix is 
visualised during a speculum examination 
and a weak solution of acetic acid is applied 
to stain abnormal epithelial lesions white.  
HIV and cervical cancer
HIV infection is associated with high 
incidences of CIN lesions and also 
persistent HPV infection.14,15 An important 
study from Durban showed that HIV 
infection may cause HPV infection to 
progress quickly from pre-invasive disease 
to frank invasion. The HIV-positive 
population developed cervical cancer 15 
years earlier than the HIV-negative control 
group.16 A local study has shown that HIV-
infected women are also at an increased 
risk of pre-cancerous lesions.15 The national 
HIV management policy includes annual 
cervical cytology. However, recently this 
has been questioned and the Western Cape 
policy states that HIV-positive women 
should be tested every 3 years if the initial 
screen is normal. This is still more frequent 
than the national screening protocol of 
three cytology tests per woman per lifetime 
starting after the age of 30 years.
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In a nutshell
•    HPV vaccines offer a unique opportunity to change the cervical cancer scene in South 
Africa, where secondary prevention strategies have had only limited success. 
•    A well-organised effort to offer prophylactic vaccination to the whole population will 
hold tremendous benefit for future generations of women. 
•    Cervical cytology is still the most important tool for secondary prevention. It should 
be used with enthusiasm, even in vaccinated women.  
•    HPV testing holds promise for the future to be used either as a primary screen or as 
an additional test to cytology.
Single Suture
Asthma and air purifiers
A randomised controlled study of purified air administered to the ‘breathing zone’ at night to people with allergic asthma found that 
active treatment over 10 weeks resulted in improved health-related quality of life compared with placebo. The novel treatment used 
temperature-related laminar airflow with a very low particle concentration directed to the breathing zone of sleeping teenagers and 
young adults with mild to moderate allergic asthma. Bronchial inflammation also improved after 5 weeks. Changes in lung function, 
however, were not significant.
Pedroletti C. Respir Med 2009; 103: 1313-1319.
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Exercise and fat accumulation
Most studies of physical activity and obesity are usually limited by short follow-up periods and genetic selection bias, but here’s a 30-year 
study of 16 twin pairs who were discordant for leisure time physical activity habits in 1975, and who remained so throughout the next 30 
years. Magnetic resonance imaging assessed visceral, liver and intramuscular fat (the so-called high-risk fat) over time, and the authors 
conclude that regular physical activity seems to be an important factor in preventing high-risk fat accumulating, even after controlling 
for genes and childhood environment.
Leskinin T, et al. Int J Obesity 2009; doi: 10.1038/ijo.2009.170.
449
